Inclusion Criteria:

          -  Age ≥ 18 years

          -  Histological or cytological documentation of an advanced solid tumor

          -  Subject must have metastatic or recurrent disease and have failed first-line systemic
             treatment, and if indicated, failed approved second-line therapy, and for whom no
             standard therapy options are anticipated to result in a durable remission

          -  Subject must have evaluable, progressive, and measurable disease per the Response
             Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1

          -  Adequate bone marrow, liver, and renal function

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

        For Part B (expansion) in subjects metastatic urothelial carcinoma:

          -  The patient's tumor has been evaluated and prospectively identified as having FGFR 1,
             2, 3, or 4 genetic alterations.

        Exclusion Criteria:

          -  Patients who have received adequate prior treatment with a highly selective FGFR
             inhibitor

          -  Patients with other major uncontrolled medical conditions, e.g., recent myocardial
             infarction, stroke, diabetes, active hepatitis

          -  Patients who have received prior systemic anticancer therapy ≤ 3 weeks prior to study
             start (6 weeks for nitrosourea, antibodies, or mitomycin-C)

          -  Patients diagnosed with another primary malignancy within 3 years prior to study
             start, with the exception of adequately treated basal cell carcinoma, squamous cell
             carcinoma, or other non-melanomatous skin cancer, or carcinoma in situ of the uterine
             cervix

          -  Patients with glioblastoma multiforme

          -  Patient has a primary neoplasm of the brain or known uncontrolled metastases to the
             central nervous system (CNS).